- 1
- 2
GenScript
GenScript is a global biotech company (Stock Code: 1548. HK) with 4,000 employees worldwide. Founded in 2002, GenScript business encompass four major categories in synthetic biology, protein analysis and purification, biologics development and manufacturing, and cell therapy.
Ms. Hong Qian
Head of Catalog Product Unit
Mr. Paul Kao
VP, Business Development, Life Science GroupGenscript Biotech Corp
Founded in 2002, GenScript is committed to making humans and environment healthier through innovation. With its over 3,000 employees globally and R&D centers in the U.S., China and Europe, GenScript has become a global leader in providing research, biologics development services, synthetic biology products as well as a world class leader in cell therapy to help patients conquer serious diseases
Dr. Zhenyan Yan
VP Corporate DevelopmentJianmin Pharma Group
Jianmin Group (600976.SSE) is an integrated pharmaceutical company with a major focus on pediatric product development, manufacture, and marketing. Founded in 1953, headquartered in Wuhan, the largest city in Central China, its history can be traced back to 17th century. Jianmin has been a famous pharma brand in China among children and their parents for generations. Its rich pediatric portfolio ranges from nutrition, hematology, respiratory, digestive, CNS, to infections and common cold as well.
Mr Wei Li
Head of Business DevelopmentMyriad Genetics
Myriad Genetics is a technology-enabled molecular diagnostics company, with worldwide presence. Our genetic tests play in Oncology, Women's Health (e.g., prenatal), and Mental Health areas.
Jackie Z
Business Development LeadShanghai Henlius Biotech
Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,
Mr. Jean-Baptiste Duval
VP International OperationsShanghai Medicilon
CRO based in Shanghai
Ms. Sally Tang
Director of Business DevelopmentMingzhu Zhang
VP of Business DevelopmentDr. TAO YE
Director of business developmentSOTERA HEALTH COMPANY
Sotera Health is driven by its mission, Safeguarding Global Health®. Along with our three best-in-class businesses – Sterigenics®, Nordion®and Nelson Labs®– we are a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry.